China SXT Pharmaceuticals (SXTC) Debt to Equity: 2018-2025
- China SXT Pharmaceuticals' Debt to Equity fell 98.99% to $0.01 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.45, marking a year-over-year decrease of 31.78%. This contributed to the annual value of $0.05 for FY2025, which is 18.06% up from last year.
- As of Q3 2025, China SXT Pharmaceuticals' Debt to Equity stood at $0.01, which was down 90.19% from $0.05 recorded in Q1 2025.
- Over the past 5 years, China SXT Pharmaceuticals' Debt to Equity peaked at $0.76 during Q1 2021, and registered a low of $0.00 during Q1 2022.
- Its 3-year average for Debt to Equity is $0.12, with a median of $0.05 in 2024.
- Per our database at Business Quant, China SXT Pharmaceuticals' Debt to Equity surged by 18,592.62% in 2021 and then tumbled by 99.91% in 2022.
- Quarterly analysis of 5 years shows China SXT Pharmaceuticals' Debt to Equity stood at $0.15 in 2021, then plummeted by 47.24% to $0.08 in 2022, then rose by 22.42% to $0.10 in 2023, then soared by 406.17% to $0.50 in 2024, then plummeted by 98.99% to $0.01 in 2025.
- Its Debt to Equity was $0.01 in Q3 2025, compared to $0.05 in Q1 2025 and $0.50 in Q3 2024.
